PureTech Health plc Q2 2026 Earnings Recap

PureTech shares fell 4.1% after the results, with the clearest negative signal being a material downgrade to estimated future proceeds from its remaining Cobenfy economic rights. Management put those potential proceeds at approximately $50 million based on analyst consensus, while emphasizing the value of the earlier Royalty Pharma transaction.

Key Takeaways

• PureTech ended the first half with $220 million in cash, cash equivalents and short-term investments, and said its operational runway is expected to extend at least through the end of 2028.
• Celea raised $180 million in external financing and initiated its global Phase III SURPASS-IPF trial; PureTech retains a 35.4% equity interest plus royalties, milestones and sublicense income rights.
• Seaport completed its NASDAQ IPO in May, raising $250 million in gross proceeds. PureTech holds a 31.2% stake, valued at approximately $360 million as of September 18, 2026, and retains royalty and milestone rights.
• Gallop received Fast Track designation for relapsed/refractory high-risk MDS. PureTech owns 100% and intends to seek external capital before starting the Phase II STRIDE-MDS trial.
• The approximately $50 million estimate for future Cobenfy proceeds is based on analyst consensus and represents a material downgrade from PureTech’s last update at full year. PureTech said it has generated more than $1 billion from its collective Karuna and Cobenfy economics.